Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.170
-0.230-2.21%
Volume:2.48M
Turnover:25.19M
Market Cap:4.14B
PE:-11.47
High:10.370
Open:10.350
Low:10.080
Close:10.400
52wk High:679.500
52wk Low:9.010
Shares:407.00M
HK Float Shares:312.00M
Volume Ratio:0.63
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.887
ROE:-36.78%
ROA:-20.32%
PB:4.04
PE(LYR):-11.47
PS:100.06

Loading ...

TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist

Simply Wall St.
·
Aug 27

TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million

Bulletin Express
·
Aug 26

Transthera Sciences’ Tinengotinib Wins Conditional China NMPA Approval for Cholangiocarcinoma

Reuters
·
Aug 26

Transthera Sciences FY26 H1 Net Loss Narrows to RMB 95.47 Million; Revenue Rises to RMB 35.46 Million

Reuters
·
Aug 26

TRANSTHERA-B: Ching Fen Chan Tan Disposes of Shares, Long Position Falls to 5.76%

HK Disclosure
·
Aug 25

TRANSTHERA-B: Ghalibo (PTC) Limited Disposes of Shares, Long Position Falls to 5.76%

HK Disclosure
·
Aug 25

TRANSTHERA-B: Morningside Venture (I) Investments Limited Disposes of Shares, Long Position Falls to 5.76%

HK Disclosure
·
Aug 24

TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 5.76%

HK Disclosure
·
Aug 24

TransThera Sciences Schedules 26 August Board Meeting to Review 1H 2026 Results and Consider Interim Dividend

Bulletin Express
·
Aug 14

TransThera Sciences Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 14

TRANSTHERA-B: Future Industry Investment Fund II (Limited Partnership) Disposes of Shares, Long Position Falls to 5.85%

HK Disclosure
·
Aug 10

China NMPA Approves TransThera’s Yochanra for FGFR Inhibitor-Resistant Cholangiocarcinoma

Reuters
·
Aug 07

TRANSTHERA-B Shares Jump Over 12% in Morning Trading After Core Drug Tenagotinib Gets Market Approval

Deep News
·
Aug 07

TransThera Wins China Marketing Approval for Bile Duct Cancer Drug

MT Newswires Live
·
Aug 07

Movement Alert|TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval

Market Focus
·
Aug 07

Transthera-B secures NMPA approval for Je'ente in advanced bile duct cancer treatment

Stock News
·
Aug 06

Transthera Sciences (Nanjing) - Nmpa Grants Marketing Approval for Yochanra (Tinengotinib Tablets)

THOMSON REUTERS
·
Aug 06

Genecare Development Reduces Stake in TRANSTHERA-B, Sells 467,500 Shares at Approximately HK$12.58 Each

Stock News
·
Aug 06

TRANSTHERA-B: Morningside Venture (I) Investments Limited Sees Disposal of Shares, Long Position Falls to 6.87%

HK Disclosure
·
Aug 06

TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 6.87%

HK Disclosure
·
Aug 06